SCHEMBL5534878

SCHEMBL5534878

[O]c1ccc(N2CCC(Nc3ccccc3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME3 Q16798 3/20 0.47
CARM1 Q86X55 1/20 0.47
PRMT6 Q96LA8 1/20 0.47
MAPT P10636 2/20 0.43
CCR6 P51684 1/20 0.43
ALDH1A1 P00352 1/20 0.43
ME2 P23368 1/20 0.42
ME1 P48163 1/20 0.42
GLA P06280 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DRD2 P14416 3/20 0.41
DRD3 P35462 3/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA5A P35218 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542047 0.84 DRD2 (0.45) MAPTALDH1A1GLASMN1; SMN2DRD2
SCHEMBL5537271 0.84 POLB (0.58) MAPTALDH1A1SMN1; SMN2HDAC1HDAC8
SCHEMBL5534883 0.84 ME3 (0.61) ME3CARM1PRMT6MAPTALDH1A1
SCHEMBL5541176 0.84 CARM1 (0.47) ME3CARM1PRMT6MAPTCCR6
SCHEMBL5542321 0.83 KDM4E (0.58) MAPTALDH1A1SMN1; SMN2EPHX2MEN1
SCHEMBL7600532 0.81 ALDH1A1 (0.60) MAPTALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL5542611 0.81 CA2 (0.49) MAPTHDAC1HDAC8HDAC6CA12
SCHEMBL7845356 0.80 ALDH1A1 (0.45) ME3CARM1PRMT6MAPTALDH1A1
SCHEMBL5547883 0.80 HDAC1 (0.44) MAPTALDH1A1SMN1; SMN2HDAC1HDAC8
SCHEMBL5536338 0.79 KMT2A (0.49) ME3MAPTALDH1A1EPHX2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ME3 146/4885CARM1 1867/4885PRMT6 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.